TITLE

JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients

AUTHOR(S)
Pardanani, Animesh; Lasho, Terra L.; Hussein, Kebede; Schwager, Susan M.; Finke, Cristy M.; Pruthi, Rajiv K.; Tefferi, Ayalew
PUB. DATE
April 2008
SOURCE
Mayo Clinic Proceedings;Apr2008, Vol. 83 Issue 4, p457
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The JAK2V617F mutation is recurrent in polycythemia vera and essential thrombocythemia, which are myeloproliferative neoplasms (MPN5) frequently associated with arterial and/or venous thromboembolism. More recently, the JAK2V617F mutation has been Identified as a surrogate marker for subclinical or "occult" clonal myeloproliferation in patients with splanchnic venous thrombosis. However, information is limited regarding JAK2V6I7F- associated thrombosis outside the splanchnic district in patients without overt MPN. To address this issue, we retrospectively studied a consecutive series of 664 such patients who experienced thrombotic events characteristic of an MPN (500 with venous thromboembolism, 136 with stroke, and 28 with myocardial infarction at a young age). The JAK2V6I7F mutation was detected in only 6 (<1.0%) patients (5 with recurrent venous thromboembolism and 1 with stroke), and the mutant allele burden was low in all Instances (range, 2.2%-75%). None of these 6 patients developed either overt MPN or recurrent thrombosis after a median follow-up of 40 months. We conclude that the prevalence of the JAK2V617F mutation in patients with nonspianchnic venous thrombosis In the absence of MPN is too low to warrant mutation screening as part of the hypercoagulable work-up. Our study also suggests that the natural history of a JAK2V617F- positive "occult" MPN might be different from that of a typical MPN.
ACCESSION #
31718752

 

Related Articles

  • Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. Turpie, Alexander G.G. // American Journal of Health-System Pharmacy;11/15/2003 Supplement 7, Vol. 60, p20 

    Discusses trends and developments pertaining to factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. Mechanism of factor Xa inhibition; Management of other thrombotic diseases; Occurrence of thromboembolic diseases.

  • Thrombophiliescreening 2011: Wer soll wann untersucht werden? Graf, L.; Tsakiris, D. A. // Praxis (16618157);4/4/2012, Vol. 101 Issue 7, p465 

    Heritable thrombophilia as a concept in hemostasis has been continuously discovered parallel to the knowledge on physiology of bleeding disorders. Since the 1980s it has become increasingly popular to search for thrombophilia in patients with thromboembolism and their relatives. Although...

  • The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis. Muszbek, L.; Bagoly, Z.; Bereczky, Z.; Katona, É. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 3, p190 

    It has been known for a long time that blood coagulation factor XIII (FXIII) is essential for maintaining haemostasis, its deficiency leads to severe bleeding complication. Biochemical studies have revealed that FXIII is a key regulator of fibrinolysis and, in addition to its role in...

  • Recurrent Venous Thromboembolism in a Patient with Heterozygous Factor V Leiden Mutation. White, C. Whitney; Thomason, Angela R.; Prince, Valerie // Hospital Pharmacy;Sep2014, Vol. 49 Issue 8, p748 

    Objective: To report a patient case identifying risk for recurrent venous thromboembolism (VTE) associated with heterozygous Factor V Leiden mutation. Case Summary: A 54-year-old Caucasian male was diagnosed with heterozygous Factor V Leiden mutation in 2008 after experiencing a deep vein...

  • Prevalence of Genetic Mutations That Predispose to Thrombophilia in a Greek Cypriot Population. Angelopoulou, Katerina; Nicolaides, Andrew; Deltas, C. Constantinou // Clinical & Applied Thrombosis/Hemostasis;Apr2000, Vol. 6 Issue 2, p104 

    Several hereditary disorders, particularly those affecting the physiological anticoagulation systems, have been well established as risk factors for venous thromboembolism. In the present study, we investigated the prevalence of the following thrombogenic mutations in a Greek-Cypriots...

  • Risk of Thrombosis in Patients Homozygous and Heterozygous for Factor V Leiden in the East Bohemian Region. Dul�cek, Petr; Mal�, J.; �af�rov�, M. // Clinical & Applied Thrombosis/Hemostasis;Apr2000, Vol. 6 Issue 2, p87 

    A retrospective investigation on the frequency of thrombotic events in 227 heterozygous and 16 homozygous carriers for the factor V R506Q mutation (factor V Leiden) from 102 unrelated families in the East Bohemian region is reported. A majority of 130 of the 227 (57%) heterozygous and a minority...

  • Detection of Factor V Leiden by PCR-SSCP using GMA� Precast Elchrom Scientific Gels. Simundic, Ana-Maria; Topic, Elizabeta; Stefanovic, Mario // Clinical & Applied Thrombosis/Hemostasis;Jul2003, Vol. 9 Issue 3, p227 

    Genetic abnormalities in hemostatic proteins associated with hypercoagulability are an important hereditary risk factor for venous thrombosis. Several genetic mutations that cause hereditary disorders predisposing to thrombosis have been described, point mutation in the coagulation factor V gene...

  • Combined Heterozygous Plasminogen Deficiency and Factor V Leiden Defect in the Same Kindred. Sartori, Maria Teresa; Simioni, Paolo; Patrassi, Giovanni Maurizio; Theodoridis, Panagiotis; Tormene, Daniela; Girolami, Antonio // Clinical & Applied Thrombosis/Hemostasis;Jan2000, Vol. 6 Issue 1, p36 

    Combined plasminogen deficiency and resistance to activated protein C defect (factor V Leiden) have been described in a few families and associated with a variable occurrence of thrombotic events. Here we describe a new family with thrombophilia and the presence of hypoplasminogenemia and factor...

  • Mutacije FV Leiden, FII G20210A i MTHFR C677T kao faktori rizika za nastanak tromboze dubokih vena u toku trudnoće ili puerperijuma. Dordevic, Valentina; Rakicevic, Ljiljana; Spasic, Miloš; Miljic, Predrag; Mikovic, Danijela; Kovac, Mirjana; Radojkovic, Dragica // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar2005, Vol. 62 Issue 3, p201 

    Background. Venous thrombosis is the most common cause of obstetric morbidity and mortality during pregnancy and puerperium. The incidence of pregnancy-associated venous thrombosis varies from 1 in 1000 to 1 in 2000 deliveries. Factor V G1691A (FV Leiden), FII G20210A and MTHFR C677T mutations...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics